mTOR inhibitors for hepatocellular cancer: a forward-moving target

References

• Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet362, 1907–1917 (2003).
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Marrero JA, Rudolph L et al. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology134, 1752–1763 (2008).
   PubMed Web of Science ®Google Scholar
• Treiber G. Systemic treatment of hepatocellular carcinoma. Dig. Dis.19, 311–323 (2001).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J. Hepatol.48(Suppl. 1), S20–S37 (2008).
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol.24, 4293–4300 (2006).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V et al.; SHARP Investigators Study Group. Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): results of a Phase III randomized placebo-controlled trial (SHARP trial). J. Clin. Oncol.25, LBA1 (2007).
   Web of Science ®Google Scholar
• Cheng A, Kang Y, Chen Z et al. Randomized Phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma. J. Clin. Oncol.26, (2008) (Abstract 4509).
   Google Scholar
• Ma WW, Hidalgo M. Exploiting novel molecular targets in gastrointestinal cancers. World J. Gastroenterol.13, 5845–5856 (2007).
   PubMed Web of Science ®Google Scholar
• Pang RW, Poon RT. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology72(Suppl. 1), 30–44 (2007).
   PubMed Web of Science ®Google Scholar
• Kopelovich L, Fay JR, Sigman CC et al. The mammalian target of rapamycin pathway as a potential target for cancer chemoprevention. Cancer Epidemiol. Biomarkers Prev.16, 1330–1340 (2007).
   PubMed Web of Science ®Google Scholar
• Corradetti MN, Guan KL. Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? Oncogene25, 6347–6360 (2006).
   PubMed Web of Science ®Google Scholar
• Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer4, 335–348 (2004).
   PubMed Web of Science ®Google Scholar
• Easton JB, Houghton PJ. mTOR and cancer therapy. Oncogene25, 6436–6446 (2006).
   PubMed Web of Science ®Google Scholar
• Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov.5, 671–688 (2006).
   PubMed Web of Science ®Google Scholar
• Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell12, 9–22 (2007)
   PubMed Web of Science ®Google Scholar
• Rubio-Viqueira B, Hidalgo M. Targeting mTOR for cancer treatment. Adv. Exp. Med. Biol.587, 309–327 (2006).
   PubMedGoogle Scholar
• Seeliger H, Guba M, Kleespies A et al. Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev.26, 611–621 (2007).
   PubMed Web of Science ®Google Scholar
• Smolewski P. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs17, 487–494 (2006).
   PubMed Web of Science ®Google Scholar
• Easton JB, Kurmasheva RT, Houghton PJ. IRS-1: auditing the effectiveness of mTOR inhibitors. Cancer Cell9, 153–155 (2006).
   PubMed Web of Science ®Google Scholar
• Sahin F, Kannangai R, Adegbola O et al. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin. Cancer Res.10, 8421–8425 (2004).
   PubMed Web of Science ®Google Scholar
• Sieghart W, Fuereder T, Schmid K et al. Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation83, 425–432 (2007).
   PubMed Web of Science ®Google Scholar
• Baba HA, Wohlschlaeger J, Cicinnati VR et al. Phosphorylation of p70S6 kinase predicts overall survival in patients with clear margin-resected hepatocellular carcinoma. Liver Int. DOI: 10.1111/j.1478-3231.2008.01798.x (2008) (Epub ahead of print).
   Google Scholar
• Villanueva A, Chiang DY, Newell P et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology135(6), 1972–1983 (2008).
   PubMed Web of Science ®Google Scholar
• Schmitz KJ, Wohlschlaeger J, Lang H et al. Activation of the ERK and AKT signaling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J. Hepatol.48, 83–90 (2008).
   PubMed Web of Science ®Google Scholar
• Dancey JE. Inhibitors of the mammalian target of rapamycin. Expert Opin. Investig. Drugs14, 313–328 (2005).
   PubMed Web of Science ®Google Scholar
• Huynh H, Chow KP, Soo KC et al. RAD001 (everolimus) inhibits tumor growth in xenograft models of human hepatocellular carcinoma. J. Cell. Mol. Med. DOI: 10.1111/j.1582-4934.2008.00364.x (2008) (Epub ahead of print).
   Google Scholar
• Rizell M, Lindner P. Inhibition of mTOR suppresses experimental liver tumours. Anticancer Res.25, 789–793 (2005).
   PubMed Web of Science ®Google Scholar
• Schumacher G, Oidtmann M, Rueggeberg A et al. Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. World J. Gastroenterol.11, 1420–1425 (2005).
   PubMed Web of Science ®Google Scholar
• Semela D, Piguet AC, Kolev M et al. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J. Hepatol.46, 840–848 (2007).
   PubMed Web of Science ®Google Scholar
• Piguet AC, Semela D, Keogh A et al. Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. J. Hepatol.49, 78–87 (2008).
   PubMed Web of Science ®Google Scholar
• Watson CJ, Friend PJ, Jamieson NV et al. Sirolimus: a potent new immunosuppressant for liver transplantation. Transplantation67, 505–509 (1999).
   PubMed Web of Science ®Google Scholar
• Chang GJ, Mahanty HD, Quan D et al. Experience with the use of sirolimus in liver transplantation – use in patients for whom calcineurin inhibitors are contraindicated. Liver Transpl.6, 734–740 (2000).
   PubMed Web of Science ®Google Scholar
• Toso C, Meeberg GA, Bigam DL et al.De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation83, 1162–1168 (2007).
   PubMed Web of Science ®Google Scholar
• Kneteman NM, Oberholzer J, Al Saghier M et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl.10, 1301–1311 (2004).
   PubMed Web of Science ®Google Scholar
• Zhou J, Fan J, Wang Z et al. Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: report of an initial experience. World J. Gastroenterol.12, 3114–3118 (2006).
   PubMed Web of Science ®Google Scholar
• Zimmerman MA, Trotter JF, Wachs M et al. Predictors of long-term outcome following liver transplantation for hepatocellular carcinoma: a single-center experience. Transpl. Int.20, 747–753 (2007).
   PubMed Web of Science ®Google Scholar
• Zimmerman MA, Trotter JF, Wachs M et al. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl.14, 633–638 (2008).
   PubMed Web of Science ®Google Scholar
• Chen YB, Sun YA, Gong JP. Effects of rapamycin in liver transplantation. Hepatobiliary Pancreat. Dis. Int.7, 25–28 (2008).
   PubMed Web of Science ®Google Scholar
• Rizell M, Andersson M, Cahlin C et al. Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J. Clin. Oncol.13, 66–70 (2008).
   PubMed Web of Science ®Google Scholar
• Decaens T, Luciani A, Itti E et al. Pilot study of sirolimus in cirrhotic patients with advanced hepatocellular carcinoma. Hepatology48(Suppl.), 953A (2008) (Abstract 1453).
   PubMed Web of Science ®Google Scholar
• Siegel AB, Cohen EI, Ocean A et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J. Clin. Oncol.26(18), 2992–2998 (2008).
   PubMed Web of Science ®Google Scholar
• Treiber G, Wex T, Malfertheiner P. Impact of different anticancer regimens on biomarkers of angiogenesis in patients with advanced hepatocellular cancer. J. Cancer Res. Clin. Oncol.135(2), 271–281 (2009).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology48(4), 1312–1327 (2008).
   PubMed Web of Science ®Google Scholar
• Thomas MB, Chadha R, Glover K et al. Phase II study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer110(5), 1059–1067 (2007).
   PubMed Web of Science ®Google Scholar
• Treiber G, Wex T, Rocken C et al. Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma. J. Cancer Res. Clin. Oncol.132, 699–708 (2006).
   PubMed Web of Science ®Google Scholar
• Newell P, Roayaie S, Schwartz M et al. Mechanisms of Ras pathway activation in HCC patients, and combination therapies blocking Ras (sorafenib) and mTOR pathways (rapamycin) in vivo. Hepatology48(Suppl.), 983A (2008) (Abstract 1521).
   Web of Science ®Google Scholar
• Attia S, Holen KD, Thomas JP et al. Biologic study of the effects of octreotide-LAR on growth hormone in unresectable and metastatic hepatocellular carcinoma. Clin. Adv. Hematol. Oncol.6, 44–54 (2008).
   PubMedGoogle Scholar
• Llovet JM, Di Bisceglie AM, Bruix J et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J. Natl Cancer Inst.100, 698–711 (2008).
   PubMed Web of Science ®Google Scholar